Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2014

View Archived Issues

Merrimack Pharmaceuticals begins phase II trial of MM-302 in HER2-positive breast cancer

NIPER reports novel PON 1 enzymes

Forma Therapeutics and Paradigm enter into molecular profiling collaboration

Characterization of potential disease-causing mutations in tRNA genes

AstraZeneca reports topline results from pivotal studies of lesinurad for gout

Seattle Genetics begins phase I study of SGN-CD70A

Novogen receives funding to begin studies in muscular dystrophy

Advanced Proteome Therapeutics updates progress of cancer program

Pfizer presents DGAT2 inhibitors with activity in preclinical models of metabolic disease

23andMe and Pfizer collaborate to investigate genetics of inflammatory bowel disease

Flex Pharma reports data for proprietary product for preventing muscle cramps

Novel small-molecule GK-GKRP inhibitors with the ability to lower blood glucose levels in vivo

First-in-class APOBEC3 enzyme inhibitors identified as potential oncolytic candidates

Merck & Co. reports glucokinase activators as diabetes treatment candidates

Novel ACC-beta inhibitors described by Boehringer Ingelheim

New vaccines for Francisella tularensis infection

Researchers at Janssen disclose novel agents for RSV infection

Roche synthesizes new LMP7 inhibitors

FDA approves Belsomra for insomnia

Insys Therapeutics submits NDA for new oral formulation of dronabinol

RedHill Biopharma gains option for RP-101 from RESprotect

Lithera changes name to Neothetics

Phase II trial to test safety and efficacy of fexinidazole in Chagas disease

Sirona subsidiary receives funding for anti-aging project

Rigel's R-348 misses endpoints in keratoconjunctivitis sicca trial

Medicure reports data from phase II trial of Tardoxal in tardive dyskinesia

Allergan acquires lidocaine for interstitial cystitis/bladder pain syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...